Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-03-2012 | Original Paper

Expressions of MAGE-A10 and MAGE-A11 in breast cancers and their prognostic significance: a retrospective clinical study

Authors: Yishui Lian, Meixiang Sang, Chunyan Ding, Xinliang Zhou, Xiaojie Fan, Yingying Xu, Weihua Lü, Baoen Shan

Published in: Journal of Cancer Research and Clinical Oncology | Issue 3/2012

Abstract

Purpose

Melanoma-associated antigens-A (MAGE-A) family is a group of well-characterized cancer/testis antigens (CTA), because they are strictly tumor specific and are shared by many kinds of tumors. However, the expression pattern of MAGE-A10 and MAGE-A11 in breast cancer patients is still unclear. The purpose of our study is to investigate the expression pattern and prognostic significance of MAGE-A10 and MAGE-A11 in breast cancer patients.

Methods

Formalin-fixed and paraffin-embedded tissues and the clinicopathological parameters from 75 primary breast cancer patients were collected. The expressions of MAGE-A10 and MAGE-A11 proteins were immunohistochemically detected, and the association of MAGE-A10 and MAGE-A11 expressions with the clinicopathological parameters and the survival of breast cancer patients were analyzed.

Results

The expression rates of MAGE-A10 and MAGE-A11 in breast cancer specimens were 73.3 and 52.0%, respectively. MAGE-A11 expression was more frequent in estrogen-receptor (ER)-positive breast carcinomas compared with ER-negative breast carcinomas (P = 0.004). MAGE-A11 expression was positively associated with HER-2 expression (P = 0.003). Overall survival of patients with MAGE-A11-negative expression was significantly longer than those patients with positive MAGE-A11 expression (P = 0.030), but no difference of overall survival was found between patients with MAGE-A10-negative and -positive expression (P = 0.881).

Conclusions

MAGE-A10 and MAGE-A11 are tumor-specific antigens, and MAGE-A11 expression probably is a potential poor prognostic factor for breast cancer patients.

Bandić D, Juretić A, Sarcević B, Separović V, Kujundzić-Tiljak M, Hudolin T, Spagnoli GC, Cović D, Samija M (2006) Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study. Croat Med J 47(1):32–41PubMed

Bergeron A, Picard V, LaRue H, Harel F, Hovington H, Lacombe L, Fradet Y (2009) High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. Int J Cancer 125(6):1365–1371PubMedCrossRef

Brasseur F, Rimoldi D, Liénard D, Lethé B, Carrel S, Arienti F, Suter L, Vanwijck R, Bourlond A, Humblet Y (1995) Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 63(3):375–380PubMedCrossRef

Busam KJ, Iversen K, Berwick M, Spagnoli GC, Old LJ, Jungbluth AA (2000) Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters. Mod Pathol 13(4):459–465PubMedCrossRef

De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, Brasseur F, van der Bruggen P, Lethé B, Lurquin C (1994) Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 40(5):360–369PubMedCrossRef

Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ (2007) Global cancer facts & figures 2007. American Cancer Society, Atlanta

Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ, Panel members (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer. Ann Oncol 16(10): 1569–1583

Karn T, Pusztai L, Ruckhäberle E, Liedtke C, Müller V, Schmidt M, Metzler D, Wang J, Coombes KR, Gätje R, Hanker L, Solbach C, Ahr A, Holtrich U, Rody A, Kaufmann M (2011) Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. Eur J Cancer 48(1):12–23

Kufer P, Zippelius A, Lutterbüse R, Mecklenburg I, Enzmann T, Montag A, Weckermann D, Passlick B, Prang N, Reichardt P, Dugas M, Köllermann MW, Pantel K, Riethmüller G (2002) Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease. Cancer Res 62(1):251–261PubMed

Ohman Forslund K, Nordqvist K (2001) The melanoma antigen genes–any clues to their functions in normal tissues? Exp Cell Res 2001 265(2): 185–194

Otte M, Zafrakas M, Riethdorf L, Pichlmeier U, Loning T, Jänicke F, Pantel K (2001) MAGE-A gene expression pattern in primary breast cancer. Cancer Res 61(18):6682–6687PubMed

Polyak K (2007) Breast cancer: origins and evolution. J Clin Invest 117(11):3155–3163PubMedCrossRef

Rabindran SK (2005) Antitumor activity of HER-2 inhibitors. Cancer Lett 227(1):9–23PubMedCrossRef

Rimoldi D, Salvi S, Schultz-Thater E, Spagnoli GC, Cerottini JC (2000) Anti-MAGE-3antibody 57B and anti-MAGE-1 antibody 6C1 can be used to study different proteins of the MAGE-A family. Int J Cancer 86(5):749–751PubMedCrossRef

Rogner UC, Wilke K, Steck E, Korn B, Poustka A (1995) The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28. Genomics 29(3):725–731PubMedCrossRef

Ross JS, Fletcher JA (1998) The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem cells 16(6):413–428PubMedCrossRef

Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ (2003) The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8(4):307–325PubMedCrossRef

Sang M, Wang L, Ding C, Zhou X, Wang L, Lian Y, Shan B (2011a) Melanoma-associated antigen genes-an update. Cancer Lett 302(2):85–90PubMedCrossRef

Sang M, Lian Y, Zhou X, Shan B (2011b) MAGE-A family: attractive targets for cancer immunotherapy. Vaccine 29(47):8496–8500PubMedCrossRef

Scanlan MJ, Simpson AJ, Old LJ (2004) The cancer/testis genes: review, standardization, and commentary. Cancer Immun 23:1

Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5(8):615–625PubMedCrossRef

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182PubMedCrossRef

Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 1989, 244(4905): 707–712

Sugita M, Geraci M, Gao B, Powell RL, Hirsch FR, Johnson G, Lapadat R, Gabrielson E, Bremnes R, Bunn PA, Franklin WA (2002) Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res 62(14):3971–3979PubMed

Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254(5038):1643–1647PubMedCrossRef

Weigelt B, Reis-Filho JS (2009) Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 6(12):718–730PubMedCrossRef

Yeon CH, Pegram MD (2005) Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs 23(5):391–409PubMedCrossRef

Zendman AJ, Ruiter DJ, Van Muijen GN (2003) Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol 194(3):272–288PubMedCrossRef

Title: Expressions of MAGE-A10 and MAGE-A11 in breast cancers and their prognostic significance: a retrospective clinical study
Authors: Yishui Lian
Meixiang Sang
Chunyan Ding
Xinliang Zhou
Xiaojie Fan
Yingying Xu
Weihua Lü
Baoen Shan
Publication date: 01-03-2012
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 3/2012
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-011-1122-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Expressions of MAGE-A10 and MAGE-A11 in breast cancers and their prognostic significance: a retrospective clinical study

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2012

Functional outcome after different oncological interventions in head and neck cancer patients

Trends in incidence, tumour sites and tumour stages of oral and pharyngeal cancer in Northern Germany

Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes

Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients

VEGF gene alternative splicing: pro- and anti-angiogenic isoforms in cancer

Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page